Sequence
Sequence is a subsidiary corporation of Empyrean Systems. The genetics and pharmaceutical research company was just launched in March of 2101 as a rebranding of VorTECH - which had just been acquired by the pharmaceutical giant. According to public reports, VorTECH's upper management staff was replaced by in-house employees. Most notably, Sequence received a whole new research department and was transferred access to multiple medical labs owned by Empyrean Systems. Namely, the head of research was replaced with Moira Evans, a leading researcher in genetic fields.
As of yet, Sequence has only announced one research project to the public - a supplement meant to boost the willpower, drive, and - most importantly - luck of users. While not available to the public at the moment, Good Luck To-Go seems to be in the final stages of testing. There are other trademarks that have been filed by Sequence since its acquisition by Empyrean Systems: public records show the acquisition of Vital-V and Ferrotype. Neither project has been announced to the public.
Founding Date
2101
Type
Corporation, Pharmaceutical
Alternative Names
VorTECH, Vortex Technologies
Ruling Organization
Comments